为了评估弥散和灌注 MRI 衍生参数是否可以无创预测原发性中枢神经系统弥漫性大 B 细胞淋巴瘤 (PCNS-DLBCL) 的 PD-L1 和 Ki-67 状态。我们回顾性分析了 DWI、DSC-PWI 和形态学数据。 88 名 PCNS-DLBCL 患者的 MRI (mMRI)。使用卡方检验或 Fisher 精确检验比较 mMRI 特征。使用 Mann-Whitney 比较不同分子状态的 PCNS-DLBCL 的最小 ADC (ADCmin)、平均 ADC(ADCmean)、相对最小 ADC (rADCmin)、相对平均 ADC (rADCmean) 和相对最大 CBV (rCBVmax) 值U测试。通过受试者工作特征曲线评估诊断性能。PD-L1高表达的PCNS-DLBCL表现出比PD-L1低表达的PCNS-DLBCL显着更高的ADCmin值。与低 Ki-67 状态的 PCNS-DLBCL 相比，高 Ki-67 状态的 PCNS-DLBCL 的 ADCmean 和 rADCmean 值显着较低。其他 ADC、CBV 参数和 mMRI 特征未显示与这些分子状态有任何关联 ADC 值在评估 PD-L1 和 Ki-67 状态时的诊断效能相对较低，曲线下面积 (AUC) 值小于 0.7 .DWI 衍生的 ADC 值可以提供有关 PCNS-DLBCL 中 PD-L1 和 Ki-67 状态的一些相关信息，但由于诊断性能相当低，可能不足以预测其表达。© 2024。作者。

To assess whether diffusion and perfusion MRI derived parameters could non-invasively predict PD-L1 and Ki-67 status in primary central nervous system diffuse large B-cell lymphoma (PCNS-DLBCL).We retrospectively analyzed DWI, DSC-PWI, and morphological MRI (mMRI) in 88 patients with PCNS-DLBCL. The mMRI features were compared using chi-square tests or Fisher exact test. Minimum ADC (ADCmin), mean ADC(ADCmean), relative minimum ADC (rADCmin), relative mean ADC (rADCmean), and relative maximum CBV (rCBVmax) values were compared in PCNS-DLBCL with different molecular status by using the Mann-Whitney U test. The diagnostic performances were evaluated by receiver operating characteristic curves.PCNS-DLBCL with high PD-L1 expression demonstrated a significantly higher ADCmin value than those with low PD-L1. The ADCmean and rADCmean values were significantly lower in PCNS-DLBCL with high Ki-67 status compared with those in low Ki-67 status. Other ADC, CBV parameters, and mMRI features did not show any association with these molecular statuses The diagnostic efficacy of ADC values in assessing PD-L1 and Ki-67 status was relatively low, with area under the curves (AUCs) values less than 0.7.DWI-derived ADC values can provide some relevant information about PD-L1 and Ki-67 status in PCNS-DLBCL, but may not be sufficient to predict their expression due to the rather low diagnostic performance.© 2024. The Author(s).